Millennium Management LLC Invests $1.39 Million in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Millennium Management LLC purchased a new position in CARGO Therapeutics, Inc. (NASDAQ:CRGX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 96,342 shares of the company’s stock, valued at approximately $1,389,000. Millennium Management LLC owned 0.21% of CARGO Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of CRGX. Tower Research Capital LLC TRC lifted its holdings in CARGO Therapeutics by 565.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock worth $84,000 after buying an additional 4,929 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of CARGO Therapeutics during the 4th quarter worth $141,000. Invesco Ltd. purchased a new stake in shares of CARGO Therapeutics during the 4th quarter worth $165,000. Intech Investment Management LLC purchased a new stake in shares of CARGO Therapeutics during the 4th quarter worth $181,000. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of CARGO Therapeutics during the 4th quarter worth $183,000. Hedge funds and other institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Price Performance

Shares of NASDAQ CRGX opened at $4.50 on Wednesday. The stock has a market capitalization of $207.50 million, a P/E ratio of -1.06 and a beta of 0.47. The business has a fifty day moving average price of $4.23 and a 200 day moving average price of $8.03. CARGO Therapeutics, Inc. has a 1-year low of $3.00 and a 1-year high of $25.45.

CARGO Therapeutics Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.